Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects millions worldwide. While early intervention can slow disease progression, traditional diagnostics rely on motor symptoms that often appear in later stages. Ultra-sensitive biomarker detection is transforming Parkinson’s research by enabling earlier detection and monitoring of disease progression.

This publication brief explores how Simoa® technology enables precise quantification of key Parkinson’s disease biomarkers. Alpha-synuclein (α-syn) and its phosphorylated form (pS129-α-syn) are closely associated with Parkinson’s pathology and have emerged as promising plasma biomarkers due to their high sensitivity and specificity. Neurofilament light chain (NfL) serves as an indicator of neuronal damage, while glial fibrillary acidic protein (GFAP) provides insights into neuroinflammation. Tau, another critical biomarker, is linked to neurodegenerative disease progression.

By providing femtogram-level sensitivity, Simoa technology allows for accurate biomarker measurement in both cerebrospinal fluid (CSF) and blood, supporting less invasive and more scalable diagnostic approaches.

What You’ll Learn:

• How ultrasensitive biomarker detection is improving early Parkinson’s disease diagnosis
• The role of blood-based biomarkers in monitoring disease progression
• How Simoa technology delivers unmatched sensitivity for Parkinson’s research
• The advantages of custom assay development and biomarker testing services

Download the publication brief to explore how Simoa technology is shaping the future of Parkinson’s disease biomarker research.